HDAC9 and neoplasm: Although their loss early on in tumorigenesis may alter the ultimate tumor presentation, clinically, these tumors may have become more addicted to these factors in tumor maintenance; this may allow for therapeutic intervention of these tumors—either through indirect mechanisms (such as with HDAC inhibition in FP-RMS) or with directly-targeted molecular glues or protein degraders as these technologies improve.